adenosine/atrophy

The present invention relates to 8-pyrazol-xanthine derivatives, pharmaceutical compositions containing them, and methods of treating conditions and diseases mediated by the adenosine A.sub.2B receptor activity, by employing such compounds. Accordingly, the present invention provides compounds of

TECHNICAL FIELD The present invention relates to a method of protecting or delaying retinal neurons from cell death by administering purinergic receptor agonists such as uridine 5'-di-and triphosphates, cytidine 5'-di-and triphosphates, dinucleoside polyphosphates, and their analogs

TECHNICAL FIELD The present disclosure relates to a series of substituted fused tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are

TECHNICAL FIELD This invention relates to treatment of neurodegenerative disorders, and more particularly to Alzheimer's disease and Parkinson's disease. BACKGROUND Oxidative stress plays a role in neurodegeneration, regardless of etiology. Physical trauma or secondary effects of insult to the

This application is a 371 of PCT/GB99/02924 filed Sep. 3, 1999. The present invention relates to 4-quinolderivnatives and their use in therapy. In particular, the present invention relates to the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The

FIELD OF THE INVENTION The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose) polymerase ["poly(ADP-ribose) polymerase" or "PARP", which is also sometimes called "PARS" for poly(ADP-ribose) synthetase]. More particularly, the invention relates to

The present invention relates to 4-quinolinylmethanol derivatives and their use in therapy. In particular, the present invention relates to the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The invention relates in particular to adenosine

FIELD OF THE INVENTION The present invention relates to methods and compositions for inhibiting and treating osteoarthritis and for promoting cartilage formation, particularly liposomes and liposomal compositions containing an adenosine receptor agonist, or an analog or derivative thereof or a

BACKGROUND OF THE INVENTION This invention relates to novel tricyclic fused pyrimidine derivatives useful as medicines Pyrazolo[3,4-d]pyrimidine derivatives having, among others, analgesic, antiinflammatory and diuretic actions are disclosed in Japanese Unexamined Patent Publication No. 31694/1978,